BPIQ Blog

Summary: The TVTX PDUFA for Sparsentan is coming up on February 17 for IgA Nephropathy (IgAN) The market reacted positively when Phase 3...

We're coming to the end of January as we set our sights on Feb and the remaining Q1 events. We have a number of readouts coming including...

Let's review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and...

Summary: ASCO-GU is taking place from Feb 16-19 and abstracts will be released Feb 13 This conference will focus on genitourinary cancers...

Summary: GTHX Trilaciclib Phase 3 data in colorectal cancer is expected in February 2023 This is initial PRESERVE 1 CRC data and initial...

Originally posted 1/25/23; last updated 4/13/23 Summary: Many exciting Alzheimer's disease catalysts are coming throughout the year See...

Summary: SAVA Ph2 Open label study topline data was reported today, 1/24/23 While the data was reported as positive, the market did not...

SUMMARY Yesterday, AGEN presented updated data on its lead candidate, an anti-CTLA-4 at ASCO-GI23 The AGEN ASCO-GI23 presentation...

This weekend we have the ASCO-GI biomedical meeting happening with some new data coming. See our full ASCO-GI post with catalyst...

Let's review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and...

Summary: ASCO-GI starts this Thursday, January 19, 2023 This conference focuses on indications including stomach cancer, gastrointestinal...

Let's review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and...

Last week we saw a number of buyouts and had the JP Morgan conference. As we move through this quarter we see a number of PDUFA events...

See Table 1 for all Stock Market Holidays where the NASDAQ stock market is closed. Table 1. Stock market holidays in 2023 If you are...

Last updated 1/12/2023 Summary: MDGL read out Phase 3 topline data on December 19, leading to a stock move of over +250%! Many other NASH...

Let's review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and...

We ended the previous week with the FDA approval for Lecanemab treating Alzheimer's. We'll track and share the future events as they...

Summary: The biotech sector saw many exciting events and readouts in 2022 While smid-cap biopharmas were down more than 20% during 2022,...

Summary: Biogen and Eisai's asset Lecanemab has a PDUFA date set for Friday 1/6/23 Lecanemab targets and effectively reduces beta-amyloid...

Last week we saw the TGTX get approval and the stock is up 50%. As we set our sights on January there's lot to be on the lookout for. We...